In another study, patients age 1 to 17 years with low-risk B-ALL, defined by the absence of high-risk genetic features (BCR-ABL1, KMT2A-AFF1) and the MRD level < 1 × 10–4 on days 33 and 78, are randomized to receive standard or reduced delayed intensification treatment (34). This evidence concerns the gene AFF1 and acute lymphoblastic leukemia.